Critical Survey: Cyclo Therapeutics (NASDAQ:CYTH) and Apogee Therapeutics (NASDAQ:APGE)

Cyclo Therapeutics (NASDAQ:CYTH) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Earnings and Valuation

This table compares Cyclo Therapeutics and Apogee Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclo Therapeutics	$1.13 million	20.71	-$20.06 million	($1.00)	-0.82
Apogee Therapeutics	N/A	N/A	-$83.99 million	($5.25)	-9.21

Cyclo Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cyclo Therapeutics and Apogee Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclo Therapeutics	-1,720.76%	-2,741.89%	-253.06%
Apogee Therapeutics	N/A	-27.14%	-23.24%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cyclo Therapeutics and Apogee Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclo Therapeutics	0	1	2	0	2.67
Apogee Therapeutics	0	0	7	0	3.00

Cyclo Therapeutics presently has a consensus target price of $2.52, indicating a potential upside of 210.70%. Apogee Therapeutics has a consensus target price of $73.00, indicating a potential upside of 50.89%. Given Cyclo Therapeutics’ higher possible upside, research analysts plainly believe Cyclo Therapeutics is more favorable than Apogee Therapeutics.

Summary

Apogee Therapeutics beats Cyclo Therapeutics on 7 of the 12 factors compared between the two stocks.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.